Discovery and design of new antigens for vaccines conferring broad spectrum protection against leptospirosis

COVALEPT est accrédité par Lyonbiopôle

Identity card

Global budget: 6116 k€

Public funding: 1908 k€

Public funders: Conseil général de l'Isère, FEDER Rhône-Alpes, FEDER Auvergne, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Grenoble Alpes Métropole, Oséo / BPI France (except FUI), Région Rhône-Alpes, Ville de Grenoble

Call for projects: FUI (FUI AAP15)

Year start: 2013

Completed project

Accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Animal Medicines

Application fields: Infectious diseases

Technological approaches / Keywords: Bioinformatics / Software, Biomanufacturing, Genetics / Genomics, Vector vaccine, Antigen discovery

Stage of development at the beginning of the project: Basic research, Discovery


Leptospirosis is a neglected bacterial disease affecting humans and various mammals with a high mortality rate. Vaccination is the most effective prevention strategy but most current vaccines do not protect against new serovars emerged in the past few years. COVALEPT will isolate and characterize virulent circulating strains from the field. Protective antigens conserved amongst Leptospira will be identified by bioinformatics, produced in native or recombinant form and assessed in vivo in order to conceive a broad spectrum vaccine for multi-species applications.       


Providing: - A leptospirosis vaccine candidate for dogs and potentially other species - Bioinformatics, molecular and biochemical tools that could accelerate the discovery and development of other bacterial antigen targets        

Innovative assets
Actual results

Innovative assets

- New broad-spectrum vaccines against Leptospirosis; - Collection of virulent circulating Leptospira strains directly isolated from infected dogs; - New genetic tools for Leptospira, insights into biology and virulence mechanisms of atypical bacteria; - New software and services offers for bacterial protective candidatesselection and antigen design; - Rationally designed extraction reagents based on chemistry of nativemembrane proteins; - Optimized host/vector couplesfor recombinant expression of membrane proteins